Vice Chairwoman Sarina Lin (Middle), as the representative of Honeybear Biosciences, accepted the“Most Promising Award” awarded by Director of the Biomedical Translation Research Center (BioTReC), Han-Chung Wu (Left), and Venture Partner, Vivo Capital LLC, Dr. Jo Shen (Right).
Honeybear Biosciences stood out at the 2025 NBRP Demo Day competition held in July, winning the “Most Promising Award” for its groundbreaking development of Taiwan’s first ARC (Antibody-Radionuclide Conjugate) drug. The company impressed judges with its innovative technology, strong team, and clear strategic vision developed through both internal innovation and international collaboration.
Honeybear’s proprietary CoNectar® platform and its ARC candidate HB001 demonstrate the company’s cutting-edge ability to combine antibodies with radioactive isotopes. This next-generation therapy enhances tumor targeting and destruction while significantly reducing side effects on healthy tissues. HB001, the first ARC of its kind in Taiwan, has entered the animal testing stage, with highly anticipated results.
Vice Chairwoman Sarina Lin, wearing a striking red suit, captivated the judges with a concise and powerful pitch at Demo Day, showcasing the company’s impressive progress from inception to clinical trial readiness in just four years. CEO Dr. Simon Chuang further impressed the panel during the Q&A session with his expertise in product positioning and clinical strategy.
Beyond its technological achievements, Honeybear is actively expanding its global footprint. It has partnered with institutions such as Singapore’s A’STAR and the University of California, San Francisco (UCSF) to build an international R&D network. The company has also raised nearly NT$300 million of funds to drive forward the development of HB001. The judging panel unanimously recognized the foresight and market potential of Honeybear’s approach, highlighting its leadership in the combination of ADCs and radiotherapy.
The Honeybear team spans R&D, manufacturing, marketing, and business management, with over 200 years of specialized industry experience. Moving forward, Honeybear will continue to leverage its CoNectar® platform to expand its product pipeline and accelerate the development of next-generation ADCs for cancer treatment—bringing new hope to cancer patients worldwide.
Honeybear’s proprietary CoNectar® platform and its ARC candidate HB001 demonstrate the company’s cutting-edge ability to combine antibodies with radioactive isotopes. This next-generation therapy enhances tumor targeting and destruction while significantly reducing side effects on healthy tissues. HB001, the first ARC of its kind in Taiwan, has entered the animal testing stage, with highly anticipated results.
Vice Chairwoman Sarina Lin, wearing a striking red suit, captivated the judges with a concise and powerful pitch at Demo Day, showcasing the company’s impressive progress from inception to clinical trial readiness in just four years. CEO Dr. Simon Chuang further impressed the panel during the Q&A session with his expertise in product positioning and clinical strategy.
Beyond its technological achievements, Honeybear is actively expanding its global footprint. It has partnered with institutions such as Singapore’s A’STAR and the University of California, San Francisco (UCSF) to build an international R&D network. The company has also raised nearly NT$300 million of funds to drive forward the development of HB001. The judging panel unanimously recognized the foresight and market potential of Honeybear’s approach, highlighting its leadership in the combination of ADCs and radiotherapy.
The Honeybear team spans R&D, manufacturing, marketing, and business management, with over 200 years of specialized industry experience. Moving forward, Honeybear will continue to leverage its CoNectar® platform to expand its product pipeline and accelerate the development of next-generation ADCs for cancer treatment—bringing new hope to cancer patients worldwide.
